BE903103A - Derives heterocycliques - Google Patents

Derives heterocycliques

Info

Publication number
BE903103A
BE903103A BE0/215493A BE215493A BE903103A BE 903103 A BE903103 A BE 903103A BE 0/215493 A BE0/215493 A BE 0/215493A BE 215493 A BE215493 A BE 215493A BE 903103 A BE903103 A BE 903103A
Authority
BE
Belgium
Prior art keywords
heterocyclic derivatives
alkyls
branched
alkyl
independently represent
Prior art date
Application number
BE0/215493A
Other languages
English (en)
French (fr)
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT22383/84A external-priority patent/IT1175620B/it
Priority claimed from IT21460/85A external-priority patent/IT1187678B/it
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of BE903103A publication Critical patent/BE903103A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B2205/00—Fibre drawing or extruding details
    • C03B2205/44—Monotoring or regulating the preform feed rate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BE0/215493A 1984-08-22 1985-08-22 Derives heterocycliques BE903103A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT22383/84A IT1175620B (it) 1984-08-22 1984-08-22 Derivati piridinici
IT21460/85A IT1187678B (it) 1985-07-05 1985-07-05 Procedimento di preparazione di derivati eterociclici

Publications (1)

Publication Number Publication Date
BE903103A true BE903103A (fr) 1986-02-24

Family

ID=26327905

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/215493A BE903103A (fr) 1984-08-22 1985-08-22 Derives heterocycliques

Country Status (33)

Country Link
US (2) US4801599A (instruction)
JP (2) JPS6193162A (instruction)
KR (1) KR920004482B1 (instruction)
AT (1) AT394042B (instruction)
AU (1) AU578724B2 (instruction)
BE (1) BE903103A (instruction)
BG (1) BG60409B2 (instruction)
CA (1) CA1268180A (instruction)
CH (1) CH666684A5 (instruction)
CS (1) CS403091A3 (instruction)
CY (1) CY1494A (instruction)
DE (1) DE3529997C2 (instruction)
DK (1) DK165949C (instruction)
ES (5) ES8703839A1 (instruction)
FI (1) FI81568C (instruction)
FR (1) FR2569402B1 (instruction)
GB (1) GB2164336B (instruction)
GR (1) GR852016B (instruction)
HK (1) HK52990A (instruction)
HU (1) HU196754B (instruction)
IE (1) IE58486B1 (instruction)
LU (2) LU86047A1 (instruction)
MX (1) MX159974A (instruction)
NL (2) NL193065C (instruction)
NO (2) NO167142C (instruction)
NZ (1) NZ212895A (instruction)
PH (1) PH22014A (instruction)
PT (1) PT81000B (instruction)
SA (1) SA91120277B1 (instruction)
SE (1) SE459920B (instruction)
SG (1) SG40889G (instruction)
SK (1) SK278327B6 (instruction)
ZW (1) ZW13185A1 (instruction)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions
DE3675747D1 (de) * 1985-08-21 1991-01-03 Glaxo Spa 1,4-dihydropyridinverbindungen und ihre herstellung und pharmazeutische formulierung.
ES2001104A6 (es) * 1985-08-21 1988-04-16 Glaxo Spa Un procedimiento para la preparacion de nuevos derivados sustituidos del acido 1,4-dihidro-3,5-piridindicarboxilico.
IT1204462B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204461B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1204460B (it) * 1986-02-20 1989-03-01 Glaxo Spa Derivati eterociclici
IT1233370B (it) * 1988-11-21 1992-03-27 Glaxo Spa Procedimento di preparazione di derivati diidropipiridinici utili nel trattamento di disturbi cardiovascolari
EP0395369B1 (en) 1989-04-27 1997-07-02 Canon Inc. Optical recording medium and process for production thereof
US5177202A (en) * 1990-10-09 1993-01-05 Merck & Co., Inc. 2-phenanthrenyl-carbapenems
US5196529A (en) * 1990-10-09 1993-03-23 Merck & Co., Inc. 2-phenanthrenyl carbapenem intermediates
US5132422A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5132421A (en) * 1990-10-09 1992-07-21 Merck & Co., Inc. 2-naphthyl-carbapenem intermediates
US5144028A (en) * 1990-10-09 1992-09-01 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5356889A (en) * 1990-08-01 1994-10-18 Merck & Co., Inc. 2-(9-fluorenonyl)-carbapenem intermediates
US5208329A (en) * 1990-10-09 1993-05-04 Merck & Co., Inc. 2-biphenyl carbapenem intermediates
IT1244728B (it) * 1991-02-13 1994-08-08 Glaxo Spa Impiego medicamentoso di derivati diidropiridinici
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
MXPA05001958A (es) 2002-08-19 2005-04-28 Pfizer Prod Inc Terapia de combinacion para enfermedades hiperproliferativas.
JP4901474B2 (ja) * 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
WO2006014930A2 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
EP1868577A4 (en) 2005-04-15 2009-12-09 Reddys Lab Inc Dr Lacidipine PARTICLE
US20070043088A1 (en) * 2005-08-16 2007-02-22 Eswaraiah Sajja Process for preparing lacidipine
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
ATE551059T1 (de) 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
US8026377B2 (en) * 2005-11-08 2011-09-27 Ranbaxy Laboratories, Limited Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
AR059838A1 (es) * 2006-03-14 2008-04-30 Ranbaxy Lab Ltd Formulaciones para dosis estabilizantes de estatina
MX2009000439A (es) * 2006-07-14 2009-02-04 Ranbaxy Lab Ltd Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas.
US20080089947A1 (en) * 2006-08-18 2008-04-17 Knox Clayton D Calcium Influx Inhibitors in the Treatment of Ischemia
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US8883844B2 (en) 2010-09-24 2014-11-11 Nitrogenix Inc. Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
PL2705839T3 (pl) 2012-09-10 2018-07-31 Rivopharm Sa Farmaceutyczna kompozycja zawierająca lacydypinę i proces przygotowania
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455945A (en) * 1967-06-07 1969-07-15 Smithkline Corp 4-(carboxy (and carbo-lower alkoxy)phenyl)-1,4-dihydropyridines
DE2228363A1 (de) * 1972-06-10 1974-01-03 Bayer Ag 1,4-dihydropyridine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB1409865A (en) * 1973-02-13 1975-10-15 Science Union & Cie Dihydropyridines derivatives their preparation and pharmaceu tical compositions containing them
US4307103A (en) * 1978-09-08 1981-12-22 Fujisawa Pharmaceutical Co., Ltd. Dihydropyridine derivative, processes for preparation thereof and pharmaceutical composition comprising the same
DE3018259A1 (de) * 1980-05-13 1981-11-19 Bayer Ag, 5090 Leverkusen 1,4-dihydropyridine mit unterschiedlichen substituenten in 2- und 6-position, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
DE3207982A1 (de) * 1982-03-05 1983-09-08 Bayer Ag, 5090 Leverkusen Neue 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihrer verwendung in arzneimitteln
NZ212895A (en) * 1984-08-22 1988-07-28 Glaxo Spa 1,4-dihydropyridine derivatives and pharmaceutical compositions

Also Published As

Publication number Publication date
GR852016B (instruction) 1985-12-19
FI81568B (fi) 1990-07-31
GB2164336A (en) 1986-03-19
ES546324A0 (es) 1987-03-01
AU578724B2 (en) 1988-11-03
JPS6193162A (ja) 1986-05-12
NO167142B (no) 1991-07-01
HK52990A (en) 1990-07-20
ES552051A0 (es) 1987-09-01
KR870002073A (ko) 1987-03-28
KR920004482B1 (ko) 1992-06-05
NL193065C (nl) 1998-09-08
DK165949B (da) 1993-02-15
IE58486B1 (en) 1993-09-22
DE3529997A1 (de) 1986-03-06
LU86047A1 (fr) 1986-02-28
DK378085A (da) 1986-02-23
BG60409B2 (bg) 1995-02-28
PT81000A (en) 1985-09-01
SE8503888L (sv) 1986-02-23
ZW13185A1 (en) 1986-03-19
CH666684A5 (de) 1988-08-15
ES8707932A1 (es) 1987-09-01
DK378085D0 (da) 1985-08-20
US5011848A (en) 1991-04-30
SK278327B6 (en) 1996-11-06
ES8707930A1 (es) 1987-09-01
AU4657685A (en) 1986-02-27
NL980037I1 (nl) 1999-02-01
JPH0686430B2 (ja) 1994-11-02
ES8707931A1 (es) 1987-09-01
US4801599A (en) 1989-01-31
JPH0550506B2 (instruction) 1993-07-29
FI853206A0 (fi) 1985-08-21
FR2569402B1 (fr) 1989-09-22
ES552050A0 (es) 1987-09-01
NO167142C (no) 1991-10-09
CY1494A (en) 1990-02-16
NO853293L (no) 1986-02-24
DE3529997C2 (de) 1996-01-18
AT394042B (de) 1992-01-27
HUT40625A (en) 1987-01-28
JPS6479152A (en) 1989-03-24
ES8703839A1 (es) 1987-03-01
SG40889G (en) 1989-12-22
DK165949C (da) 1993-07-05
ES552048A0 (es) 1987-09-01
CA1268180A (en) 1990-04-24
NO1999007I1 (no) 1999-04-23
SE8503888D0 (sv) 1985-08-20
MX159974A (es) 1989-10-17
HU196754B (en) 1989-01-30
ES552049A0 (es) 1988-07-01
CS403091A3 (en) 1992-06-17
GB2164336B (en) 1988-06-08
IE852054L (en) 1986-02-22
NZ212895A (en) 1988-07-28
LU88267I2 (instruction) 1994-02-03
NL8502296A (nl) 1986-03-17
GB8520924D0 (en) 1985-09-25
NL980037I2 (nl) 1999-03-01
FR2569402A1 (fr) 1986-02-28
FI81568C (fi) 1990-11-12
ES8802497A1 (es) 1988-07-01
SE459920B (sv) 1989-08-21
FI853206L (fi) 1986-02-23
SA91120277B1 (ar) 2006-05-15
PT81000B (pt) 1988-03-03
PH22014A (en) 1988-05-02
ATA245485A (de) 1991-07-15
NL193065B (nl) 1998-05-06

Similar Documents

Publication Publication Date Title
BE903103A (fr) Derives heterocycliques
BE1002167A5 (fr) Derives de l'adenosine.
DE68914292D1 (de) Zusammensetzung zur Behandlung von ischämischen Störungen in Organen.
MA26996A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin
ATE196140T1 (de) Substituierte benzylaminoquinuclidine als substanz p antagonisten
ES2056913T3 (es) Derivados heterociclicos n-substituidos por el grupo benzhidrilo; su preparacion y su aplicacion.
TNSN07178A1 (fr) N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues
EP1245249A3 (fr) Utilisation d'un composé amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
BE900345A (fr) Composition pharmaceutique ophtalmiques a base d'un derive d'acide phenylacetique.
BE903183A (fr) Nouveaux derives du benzonorbornene, leurs procedes de preparation et composition medicamenteuse et cosmetique les contenant
BE1002102A4 (fr) Derives de l'acide quinoleinecarboxylique.
FR2637286A1 (fr) Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
KR860008973A (ko) 2-피롤리돈 유도체
ATE50773T1 (de) Alkylresorcinolphosphite.
DE69005974D1 (de) Heteroaryl-3-oxo-propannitril-derivate, nützlich zur behandlung von rheumatoider arthritis und anderen autoimmunkrankheiten.
FR2870846A1 (fr) Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
CA2225780A1 (fr) Nouveaux derives de n-benzylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FI956151A0 (fi) Iskeemisissä taudeissa käyttökelpoisia bentseenijohdannaisia
DE3867652D1 (de) N-substituierte 3,4-dihydropyrimidinverbindungen als mittel zur behandlung von erkrankungen des kardiovaskularen systems.
BE905654A (fr) Derives de la armstrong 2-1,2,4-triazoline-5-one, procede pour leur preparation et leurs utilisations.
FR2666741B1 (fr) Composition therapeutique pour inhiber l'agregation plaquettaire.
DK0420224T3 (da) Anthihepatopatisk middel
ATE146481T1 (de) Epoxysuccinamidsäurederivat
BE1003229A3 (fr) Compositions pharmaceutiques antimicrobiennes, a base d'une combinaison synergique, pour l'application topique et leur procede de preparation.

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 093C0046

CCPV Grant of a supplementary protection certificate

Free format text: 093C0046, EXPIRES 20051107

RE20 Patent expired

Owner name: *GLAXO GROUP S.P.A.

Effective date: 20050822

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME: LACIDIPINE; NAT. REGISTRATION NO/DATE; 276 S 631 F 3 19920805; FIRST REGISTRATION: FR333459.8 19901107

Spc suppl protection certif: 93C0046

Filing date: 19940927

Expiry date: 20050822

Extension date: 20051107

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME: LACIDIPINE; NAT. REG.:276 S 631 F 3 19920805; FIRST REG.: FR 333459.8 19901107

Spc suppl protection certif: 93C0046

Filing date: 19930602

Expiry date: 20050822

Extension date: 20051107

RE20 Patent expired

Owner name: *GLAXO GROUP S.P.A.

Effective date: 20050822